新型冠状病毒和甲型流感病毒双价疫苗研究进展  

Progress in development of bivalent vaccines against influenza A virus and SARS-CoV-2

作　　者：郭晓炎 翟程程 王君 Guo Xiaoyan;Zhai Chengcheng;Wang Jun(School of Basic Medical Sciences,Inner Mongolia Medical University,Hohhot 010110,China;National Health Commission Key Laboratory of Biosafety,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)

机构地区：[1]内蒙古医科大学基础医学院,呼和浩特010110 [2]中国疾病预防控制中心病毒病预防控制所,国家卫生健康委员会生物安全重点实验室,北京102206

出　　处：《中华微生物学和免疫学杂志》2023年第12期986-992,共7页Chinese Journal of Microbiology and Immunology

基　　金：国家重点研发计划项目(2022YFC2304100)。

摘　　要：新型冠状病毒及其变异株在世界范围内的持续蔓延,对全球经济和公共卫生造成了严重威胁。同属于呼吸道病毒的甲型流感病毒是流感的主要病原体,其宿主范围广泛,易发生变异,每20~40年暴发一次的流感大流行、每年的季节性流感、重症流感或动物流感病毒都严重威胁公众健康。以上两种病原感染后的临床症状极为相似。针对这两种呼吸道疾病的交替流行或共同感染,开发有效的双价疫苗具有重要意义。本综述主要介绍基于不同平台的新型冠状病毒和甲型流感病毒双价疫苗的研发进展。Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and its variants continue to spread around the world,posing a great threat to global economic and public health.Influenza A virus,a major cause of influenza,has a wide host range and evolves rapidly.Influenza pandemics,which occur every 20 to 40 years,annual seasonal influenza epidemics,severe influenza and animal influenza viruses are all serious threats to public health.Clinical manifestations of infections caused by the two pathogens are very similar.It is of great significance to develop an effective bivalent vaccine for controlling alternating epidemics or co-infection of the two pathogens.This article reviewed the progress in the development of bivalent vaccines against SARS-CoV-2 and influenza A virus based on different platforms.

关 键 词：新型冠状病毒 甲型流感病毒 双价疫苗 免疫保护 

分 类 号：R392[医药卫生—免疫学]